Abbott has entered a definitive agreement with the Solvay Group for acquisition of Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets.
The details can be read here.
No comments:
Post a Comment